The AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) clinical trial found a slightly lower AAA growth rate over 2 years, but no significant effect of the ACE inhibitor perindopril or the calcium-channel blocker amlodipine15. The gene discussed is ACE; the disease is triple-A syndrome.